Wang Lai
Transaction: 06/16/2026
SELL
Change
-1,169
Price
$265.39
Filing
06/18/2026
Type
SELL
BeOne Medicines AG
ONC • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$29.51B
Growth
29.9%
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 40.2%Positive free cash flow · 8.63Manageable debt level · 0.46Healthy liquidity · 3.41Expensive earnings multiple · 115.48
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$29.51B
52W Range239.25 - 385.22
Beta0.54
Gross Margin87.49%
Oper. Margin8.37%
Profit Margin5.37%
Debt/Eq0.46
Current Ratio3.41
Quick Ratio3.08
Revenue 5Y29.93%
Price$0.00
Change0.00%
Market Cap$29.51B
52W Range239.25 - 385.22
Beta0.54
Gross Margin87.49%
Oper. Margin8.37%
Profit Margin5.37%
Debt/Eq0.46
Current Ratio3.41
Quick Ratio3.08
Revenue 5Y29.93%
FCF 5Y22.95%
Target$399.11
Target Median$409.00
Target Range340.00 - 436.00
Volume330.37K
Avg Volume243.15K
EPS Surprise1.23
Investment DNA
How strong this company looks for long-term investors
64
out of 100
Business Quality
Margins, moat, returns
51/100
Financial Strength
Debt, cash, stability
88/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
35/100
Why this score▼
Positive revenue growth · 40.2%Positive free cash flow · 8.63Manageable debt level · 0.46Healthy liquidity · 3.41Expensive earnings multiple · 115.48
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-24
Low
$340.00
Mean
$399.11
Median
$409.00
High
$436.00
Insider Transactions
Recent executive and insider activity
Lee Chan Henry
Transaction: 06/16/2026
SELL
Change
-590
Price
$265.98
Filing
06/18/2026
Type
SELL
OYLER JOHN
Transaction: 06/16/2026
SELL
Change
-333
Price
$266.69
Filing
06/18/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Wang Lai | SELL | -1,169 | $265.39 | 06/16/2026 | 06/18/2026 |
| Lee Chan Henry | SELL | -590 | $265.98 | 06/16/2026 | 06/18/2026 |
| OYLER JOHN | SELL | -333 | $266.69 | 06/16/2026 | 06/18/2026 |
| Wu Xiaobin | SELL | -1,357 | $266.76 | 06/16/2026 | 06/18/2026 |
| BAKER BROS. ADVISORS LP | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| Mooney Elizabeth Fisher | OTHER | 0 | Not reported | 06/11/2026 | 06/15/2026 |
| Sawyers Charles Lazelle | OTHER | 0 | Not reported | 06/11/2026 | 06/15/2026 |
| Riva Alessandro | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| Sharp Shalini | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| Sawyers Charles Lazelle | OTHER | 0 | Not reported | 06/11/2026 | 06/15/2026 |
| Dugan Margaret | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| Mooney Elizabeth Fisher | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| HOOPER ANTHONY C | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| BRANDICOURT OLIVIER | BUY | +18,980 | Not reported | 06/11/2026 | 06/15/2026 |
| Wang Xiaodong | BUY | +193,492 | $20.81 | 06/11/2026 | 06/15/2026 |
| Wang Xiaodong | BUY | +99,892 | Not reported | 06/11/2026 | 06/15/2026 |
| OYLER JOHN | SELL | -149 | $258.81 | 06/11/2026 | 06/15/2026 |
| OYLER JOHN | BUY | +344,669 | $20.81 | 06/11/2026 | 06/15/2026 |
| OYLER JOHN | BUY | +177,931 | Not reported | 06/11/2026 | 06/15/2026 |
| Lee Chan Henry | SELL | -428 | $257.63 | 06/11/2026 | 06/15/2026 |